A pathway-specific cell based screening system to detect bacterial cell wall inhibitors.

Prior research has shown that beta-lactamase expression in bacteria can be used as a reporter system for antibiotic activity. It was already known that certain antibiotics, like beta-lactams, trigger this expression. However, no prior work had resolved whether this response could be used to detect non-beta-lactam cell wall inhibitors. This gap motivated the development of a more specific detection system. That uncertainty drove the need for a pathway-specific screening method. No prior work had resolved how outer membrane permeability affects induction of reporter genes. This gap motivated the use of mutant strains to bypass outer membrane barriers. That uncertainty drove the inclusion of temperature-sensitive mutations in cell wall genes. No prior work had resolved whether this system could be adapted for high-throughput screening.

The aim of this study was to develop a cell-based screening system that detects bacterial cell wall inhibitors. The specific problem addressed is the difficulty in identifying non-beta-lactam compounds that inhibit cell wall biosynthesis. This study's motivation was to improve detection sensitivity by using host strains with outer membrane defects. The researchers propose that such a system could enhance antibiotic discovery efforts. This study's motivation was also to validate that beta-lactamase induction is a direct response to cell wall inhibition. The researchers propose that this system could be used in high-throughput formats. This study's motivation was also to test whether known inhibitors trigger this response at sub-MIC levels. The researchers propose that this system could identify new classes of cell wall inhibitors.

The researchers used Escherichia coli strains carrying a cloned beta-lactamase gene from Citrobacter freundii. They tested wild-type and envA-mutant hosts to compare induction responses. A murG temperature-sensitive mutation was introduced to confirm cell wall inhibition effects. Induction was measured by monitoring beta-lactamase activity in response to various compounds. The study tested known cell wall inhibitors like moenomycin, vancomycin, and fosfomycin. The protocol included a temperature shift to activate the murG mutation. Induction levels were compared at concentrations below and above the MIC. The system was optimized for high-throughput screening using standardized protocols.

Beta-lactamase induction was observed at sub-MIC concentrations in envA-mutant hosts. Moenomycin, vancomycin, and ramoplanin induced at lower concentrations than in wild-type hosts. Fosfomycin, cycloserine, and cefoxitin also triggered induction in mutant strains. At restrictive temperatures, the murG mutation caused increased beta-lactamase activity. This confirmed that cell wall inhibition directly triggers the response. Induction was not observed in wild-type hosts at low concentrations. The system detected multiple classes of cell wall inhibitors. The protocol enabled high-throughput screening of compound libraries.

The authors propose that this system detects cell wall inhibitors by measuring beta-lactamase induction. They suggest that outer membrane defects enhance sensitivity to certain inhibitors. The researchers propose that this system can identify non-beta-lactam compounds. They suggest that temperature-sensitive mutations confirm the mechanism of action. The authors propose that high-throughput screening is feasible with this setup. They suggest that the envA mutation is useful for bypassing outer membrane barriers. The researchers propose that this method improves detection of cell wall inhibitors. They suggest that this system could be used to screen for new antibiotic candidates.